X

Trial Profile

An Open Label, Two-Arm Study in Subjects With Chorioretinal Vascular Disease to Evaluate ABP 938 and Aflibercept (Eylea) in a Prefilled Syringe

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 21 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABP 938 (Primary) ; Aflibercept (Primary) ; Aflibercept (Primary)
Indications Diabetic macular oedema; Diabetic retinopathy; Retinal oedema; Retinal vein occlusion; Wet age-related macular degeneration
Focus Registrational; Therapeutic Use
Sponsors Amgen

Most Recent Events

28 Mar 2023 Status changed from active, no longer recruiting to completed.
29 Nov 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com